Skip to main content
NCBI home page
Bulletin of the New York Academy of Medicine logoLink to Bulletin of the New York Academy of Medicine
. 1978 Nov;54(10):931–943.

A physiological basis for the treatment of essential hypertension.

M A Weber, J H Laragh
PMCID: PMC1807558  PMID: 280391

Full text

PDF
931

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brunner H. R., Laragh J. H., Baer L., Newton M. A., Goodwin F. T., Krakoff L. R., Bard R. H., Bühler F. R. Essential hypertension: renin and aldosterone, heart attack and stroke. N Engl J Med. 1972 Mar 2;286(9):441–449. doi: 10.1056/NEJM197203022860901. [DOI] [PubMed] [Google Scholar]
  2. Bulpitt C. J., Dollery C. T. Side effects of hypotensive agents evaluated by a self-administered questionnaire. Br Med J. 1973 Sep 1;3(5878):485–490. doi: 10.1136/bmj.3.5878.485. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bühler F. R., Laragh J. H., Baer L., Vaughan E. D., Jr, Brunner H. R. Propranolol inhibition of renin secretion. A specific approach to diagnosis and treatment of renin-dependent hypertensive diseases. N Engl J Med. 1972 Dec 14;287(24):1209–1214. doi: 10.1056/NEJM197212142872401. [DOI] [PubMed] [Google Scholar]
  4. Bühler F. R., Laragh J. H., Vaughan E. D., Jr, Brunner H. R., Gavras H., Baer L. Antihypertensive action of propranolol. Specific antirenin responses in high and normal renin forms of essential, renal, renovascular and malignant hypertension. Am J Cardiol. 1973 Sep 20;32(4):511–522. doi: 10.1016/s0002-9149(73)80043-8. [DOI] [PubMed] [Google Scholar]
  5. Carey R. M., Douglas J. G., Schweikert J. R., Liddle G. W. The syndrome of essential hypertension and suppressed plasma renin activity. Normalization of blood pressure with spironolactone. Arch Intern Med. 1972 Dec;130(6):849–854. [PubMed] [Google Scholar]
  6. Case D. B., Wallace J. M., Keim H. J., Sealey J. E., Laragh J. H. Usefulness and limitations of saralasin, a partial competitive agonist of angioten II, for evaluating the renin and sodium factors in hypertensive patients. Am J Med. 1976 May 31;60(6):825–836. doi: 10.1016/0002-9343(76)90903-7. [DOI] [PubMed] [Google Scholar]
  7. Case D. B., Wallace J. M., Keim H. J., Weber M. A., Sealey J. E., Laragh J. H. Possible role of renin in hypertension as suggested by renin-sodium profiling and inhibition of converting enzyme. N Engl J Med. 1977 Mar 24;296(12):641–646. doi: 10.1056/NEJM197703242961201. [DOI] [PubMed] [Google Scholar]
  8. Crane M. G., Harris J. J., Johns V. J., Jr Hyporeninemic hypertension. Am J Med. 1972 Apr;52(4):457–466. doi: 10.1016/0002-9343(72)90036-8. [DOI] [PubMed] [Google Scholar]
  9. Drayer J. I., Keim H. J., Weber M. A., Case D. B., Laragh J. H. Unexpected pressor responses to propranolol in essential hypertension. An interaction between renin, aldosterone and sympathetic activity. Am J Med. 1976 May 31;60(6):897–903. doi: 10.1016/0002-9343(76)90911-6. [DOI] [PubMed] [Google Scholar]
  10. Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA. 1970 Aug 17;213(7):1143–1152. [PubMed] [Google Scholar]
  11. Gavras H., Ribeiro A. B., Gavras I., Brunner H. R. Reciprocal relation between renin dependency and sodium dependency in essential hypertension. N Engl J Med. 1976 Dec 2;295(23):1278–1283. doi: 10.1056/NEJM197612022952302. [DOI] [PubMed] [Google Scholar]
  12. Koch-Weser J. Vasodilator drugs in the treatment of hypertension. Arch Intern Med. 1974 Jun;133(6):1017–1027. [PubMed] [Google Scholar]
  13. Laragh J. H. Vasoconstriction-volume analysis for understanding and treating hypertension: the use of renin and aldosterone profiles. Am J Med. 1973 Sep;55(3):261–274. doi: 10.1016/0002-9343(73)90128-9. [DOI] [PubMed] [Google Scholar]
  14. Ledingham J. G., Bull M. B., Laragh J. H. The meaning of aldosteronism in hypertensive disease. Circ Res. 1967 Jul;21(1 Suppl):177+–177+. [PubMed] [Google Scholar]
  15. Streeten D. H., Anderson G. H., Jr, Dalakos T. H. Angiotensin blockade: its clinical significance. Am J Med. 1976 May 31;60(6):817–824. doi: 10.1016/0002-9343(76)90894-9. [DOI] [PubMed] [Google Scholar]
  16. Vaughan E. D., Jr, Laragh J. H., Gavras I., Bühler F. R., Gavras H., Brunner H. R., Baer L. Volume factor in low and normal renin essential hypertension. Treatment with either spironolactone or chlorthalidone. Am J Cardiol. 1973 Sep 20;32(4):523–532. doi: 10.1016/s0002-9149(73)80044-x. [DOI] [PubMed] [Google Scholar]
  17. Weber M. A., Case D. B., Baer L., Sealey J. E., Drayer J. I., Lopez-Overjero J. A., Laragh J. H. Renin and aldosterone suppression in the antihypertensive action of clonidine. Am J Cardiol. 1976 Nov 23;38(6):825–830. doi: 10.1016/0002-9149(76)90361-1. [DOI] [PubMed] [Google Scholar]

Articles from Bulletin of the New York Academy of Medicine are provided here courtesy of New York Academy of Medicine

RESOURCES